Generic

Fenofibrate

Indications

Fenolid is used in the treatment of hyperlipidaemias of types IIa, IIb, III, IV, and V in patients who have not responded adequately to diet and other appropriate measures.

Pharmacology

Fenofibrate is a derivative of fibric acid. After oral administration, fenofibrate rapidly hydrolyzes to its pharmacologically active form, fenofibric acid. Fenofibric acid can lower total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, total triglycerides, and very low-density lipoproteins. Furthermore, fenofibrate treatment resulted in an increase in HDL and apolipoprotein apoAI apoAII. Fenofibrate also reduces serum uric acid levels in people with hyperuricemia and normal people by increasing urinary uric acid excretion. The micronized form of Nofete (fenofibrate) has improved absorption than non-micronized formulations.

Dosage & Administration

Initially 1 capsule daily (dose form not appropriate for children or in renal impairment).

Interaction

Fenolid potentiates the action of oral anticoagulants. In patients receiving oral anticoagulants therapy, the dose should be reduced by one third on starting fenofibrate and then adjusted according to the international normalized ratio.Fenolid should not be used in combination with perhexiline maleate or with monoamino oxidase inhibitors (MAOIs).Fenolid has been given in combination with statins in resistant hyperlipidemias but the incidence of muscle problems and rhabdomyolysis is increased and care must be exercised.

Contraindications

Severe renal or hepatic impairment, existing gall bladder disease and hypersensitivity to fenofibrate.

Side Effects

Gastrointestinal (e.g. nausea, anorexia, gastric pain), pruritus, urticaria, impotence; also headache, dizziness, vertigo, fatigue, hair loss, rash, photosensitivity, raised serum transaminases, hepatitis; also reported anemia, leucopenia, thrombocytopenia.

Pregnancy & Lactation

Fenolid should not be given in pregnancy and breast-feeding.

Precautions & Warnings

Renal impairment; liver function tests recommended every 3 months for first year (discontinue treatment if significantly raised).

Therapeutic Class

Fibrates

Storage Conditions

Do not store above 30°C. Keep away from light and out of the reach of children.

Pharmaceutical Name

General Pharmaceuticals Ltd.